Furuta et al. evaluated the benefits of reducing glucocorticoid doses during remission induction for patients with ANCA-associated vasculitis. The researchers found a reduced-dose-glucocorticoid-plus-rituximab regimen was noninferior to a regimen of high-dose glucocorticoids plus rituximab in these patients.
![](https://www.the-rheumatologist.org/wp-content/uploads/2016/07/BloodCells_spanteldotru_GettyImages_500x270-150x150.jpg)